Page last updated: 2024-11-08

Epigallocatechin 3,5-Digallate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID467299
CHEMBL ID349338
CHEBI ID136605
SCHEMBL ID13287219

Synonyms (39)

Synonym
KBIO1_001322
DIVK1C_006378
SPECTRUM5_000022
SPECTRUM_000198
NCGC00178673-01
BSPBIO_002401
(-)-epigallocatechin 3,5-digallate
7-hydroxy-2-(3,4,5-trihydroxyphenyl)-5-(3,4,5-trihydroxyphenylcarbonyloxy)chroman-3-yl 3,4,5-trihydroxybenzoate
[(2r,3r)-7-hydroxy-3-(3,4,5-trihydroxybenzoyl)oxy-2-(3,4,5-trihydroxyphenyl)chroman-5-yl] 3,4,5-trihydroxybenzoate
egcdg
(-)-epigallocatechin 3,5-di-o-gallate
KBIOSS_000678
KBIO2_005814
KBIO3_001621
KBIOGR_001922
KBIO2_003246
KBIO2_000678
SPBIO_000394
SPECTRUM3_000681
SPECTRUM4_001521
SPECTRUM2_000577
SPECPLUS_000282
CHEBI:136605
CHEMBL349338
epigallocatechin 3,5-digallate
epigallocatechin 3,5,-di-o-gallate
LMPK12020125
CCG-38502
bdbm92480
epigallocatechin-3,5-digallate, c
SCHEMBL13287219
sr-05000002765
SR-05000002765-1
(-)-epigallocatechin 3,5-di-gallate
epigallocatechin 3,5-di-o-gallate
epigallocatechin 3,5-di-gallate
3,5-di-o-galloylepigallocatechin
37484-73-4
DTXSID301297609
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
catechinMembers of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)0.33000.03703.385910.0000AID1799783
Tissue-type plasminogen activatorHomo sapiens (human)IC50 (µMol)0.33000.03402.54256.6000AID1799783
Plasminogen activator inhibitor 1Homo sapiens (human)IC50 (µMol)0.33000.09104.892810.0000AID1799783
Urokinase-type plasminogen activatorMus musculus (house mouse)IC50 (µMol)0.33000.09102.92026.6000AID1799783
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
regulation of signaling receptor activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of plasminogen activationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endopeptidase activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of interleukin-8 productionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of leukotriene production involved in inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of receptor-mediated endocytosisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
defense response to Gram-negative bacteriumPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of vascular wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
cellular response to lipopolysaccharidePlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of monocyte chemotaxisPlasminogen activator inhibitor 1Homo sapiens (human)
replicative senescencePlasminogen activator inhibitor 1Homo sapiens (human)
dentinogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of odontoblast differentiationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell-matrix adhesionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processPlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
protease bindingPlasminogen activator inhibitor 1Homo sapiens (human)
serine-type endopeptidase inhibitor activityPlasminogen activator inhibitor 1Homo sapiens (human)
signaling receptor bindingPlasminogen activator inhibitor 1Homo sapiens (human)
protein bindingPlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular regionPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
plasma membranePlasminogen activator inhibitor 1Homo sapiens (human)
platelet alpha granule lumenPlasminogen activator inhibitor 1Homo sapiens (human)
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular exosomePlasminogen activator inhibitor 1Homo sapiens (human)
serine protease inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
peptidase inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1316797Inhibition of wild type His-tagged translin/trax E126A mutant (unknown origin) coexpressed in Escherichia coli BL21 cells using RNase Alert as substrate at 30 uM incubated for 10 mins prior to substrate addition monitored over 60 mins by fluorescence assa2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
A druggable target for rescuing microRNA defects.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1799783Enzymatic Assay from Article 10.1074/jbc.M109.067967: \\Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.\\2010The Journal of biological chemistry, Mar-12, Volume: 285, Issue:11
Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (16.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]